Renaissance Technologies LLC Takes Position in Immunic, Inc. $IMUX

Renaissance Technologies LLC purchased a new stake in shares of Immunic, Inc. (NASDAQ:IMUX) in the first quarter, Holdings Channel reports. The firm purchased 919,164 shares of the company’s stock, valued at approximately $1,020,000. Renaissance Technologies LLC owned about 0.07% of Immunic as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Jane Street Group LLC boosted its position in Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after purchasing an additional 152,726 shares during the last quarter. Vanguard Group Inc. grew its stake in Immunic by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock valued at $3,832,000 after purchasing an additional 219,957 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Immunic during the 3rd quarter valued at $239,000. Two Sigma Investments LP purchased a new stake in shares of Immunic during the 3rd quarter valued at $52,000. Finally, Virtu Financial LLC bought a new stake in shares of Immunic during the 3rd quarter worth $99,000. 51.82% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

IMUX has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a report on Friday, May 29th. Roth Capital restated a “buy” rating and set a $19.00 price objective on shares of Immunic in a report on Thursday, May 14th. Wolfe Research assumed coverage on shares of Immunic in a report on Friday, May 22nd. They set an “outperform” rating for the company. B. Riley Financial lowered their price objective on shares of Immunic from $40.00 to $27.00 and set a “buy” rating on the stock in a research report on Friday, May 22nd. Finally, Lifesci Capital upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, May 4th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $47.57.

Immunic Price Performance

NASDAQ:IMUX opened at $16.06 on Friday. The business has a fifty day simple moving average of $14.45 and a two-hundred day simple moving average of $12.06. Immunic, Inc. has a 1 year low of $5.06 and a 1 year high of $16.86. The company has a market capitalization of $219.06 million, a P/E ratio of -3.67 and a beta of 1.41.

Immunic (NASDAQ:IMUX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.36. As a group, analysts anticipate that Immunic, Inc. will post -4.49 earnings per share for the current year.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.